Ribociclib treatment continues to show survival benefits in postmenopausal breast cancer

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

Adding ribociclib to fulvestrant conferred a survival benefit of nearly 16 months as a first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, according to key data.

Updated OS results from the Phase 3 MONALEESA-3 study, scheduled to be presented at the ESMO Breast Cancer Congress, included a median follow-up of 5 years in women who received ribociclib ( Kisqali, Novartis) more fulvestrant compared to fulvestrant alone as a first-line endpoint, according to a Novartis press release.

Previous results presented at the 2019 ESMO Congress showed a statistically significant improvement in OS in women treated with ribociclib (median, not achieved vs 40 months; HR=0.72; 95% CI, 0.56 -0.92). The new analysis showed a median OS of 67.6 months in the ribociclib group (n=237) versus 51.8 months in the fulvestrant alone group (n=128), representing a 33% relative reduction in the risk of death (HR=0.67; 95% CI, 0.5-0.89), according to the press release.

Additionally, women who received ribociclib had a longer time to subsequent use of chemotherapy (49.2 months versus 29 months; RR=0.62; 95% CI, 0.48-0.8 ), as well as a higher estimated survival rate at 5 years (56.5 months). % versus 42.1%), the press release said.

A greater proportion of women in the ribociclib group compared to the fulvestrant alone group remained on treatment during the extended follow-up (16.5%, n=39 versus 8.6%, n=11), and the researchers did not observe no new adverse events with the combination.

Dennis J. Slamon, MD, Ph.D.

Dennis J. slammon

“MONALEESA-3 results continue to demonstrate the survival benefit of ribociclib treatment for postmenopausal women with advanced breast cancer,” Dennis J. slammondoctor, PhD, director of clinical/translational research at UCLA Jonsson Comprehensive Cancer Center, said in the press release. “Whether combined with fulvestrant or an aromatase inhibitor as a first-line setting, ribociclib offers oncologists a CDK 4/6 inhibitor with consistent benefit to provide women [hormone receptor-positive]/ HER2-negative advanced breast cancer more quality time, regardless of their disease characteristics. »

Comments are closed.